The capacity to correct a mutant gene within the context of the chromosome holds great promise as a therapy for inherited disorders but fulfilling this promise has proven to be challenging. However, steady progress is being made and the development of gene repair as a viable and robust approach is underway. Here, we present some of the recent advances that are helping to shape our thinking about the feasibility and the limitations of this technique. For the most part, these advances center on understanding the regulation of the reaction and validating its application in animal models. Gene Therapy (2005) 12, 639-646.
Introduction
Few scientific endeavors have received as much scrutiny during its early stages of development as targeted gene repair. Some of the criticism over the past 2 years has been constructive, and has helped to formulate our thinking about the reality and issues that surround this technique. Over the past several years, emphasis has been placed on elucidating and understanding the mechanism of action in an effort to stabilize the technology and eventually consider it for clinical use. It is our hope that gene repair will not suffer the same fate as other gene therapy applications that have been advanced before their time often with devastating results. 1 This review focuses on recent developments in the area of gene repair directed by oligonucleotides and offers some perspective on the mechanism and its regulation. We also point out a new, but important, issue that has arisen unexpectedly as the power of the technology is harnessed, and begins to exhibit robust and efficient correction.
Homologous recombination activities play a crucial part in the gene repair pathway
The concept of correcting single-base mutations directly in the chromosome is not new. Pioneering work by Sherman et al working in yeast, and Kucherlapati et al working in human cells (see Liu et al 2 and references therein), provided an early glimpse of the remarkable potential of single-stranded DNA in altering genomic sequences. During this period, the field moved forward at a slow pace, primarily because prokaryotes proved to be refractory to these types of approaches and thus, important model systems from bacterial cells were not readily available. Recently, however, Court et al 3 introduced the technique of 'recombineering' in bacterial
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Regulatory pathways will guide experimental design and clinical applications An understanding of the regulation of gene repair will help to define the feasibility of this approach and permit combinatorial therapy to take shape Oligonucleotide delivery must be optimized before gene repair is considered useful for clinical applications The cellular response to synthetic oligonucleotides will be a focal point of intense study More animal models must be tested to validate the overall approach chromosomes and bacterial artificial chromosomes (BACS) 4 in which short single strands of DNA are used in conjunction with a protein from bacteriophage l to alter single nucleotides in the coding regions of genes. Future work in mammalian cells will undoubtedly use this valuable information and capitalize on these advances. However, as it now stands, the progress in this field over the last 2 years has come largely from explorations into mechanisms, with some new animal data that might set the stage for clinical applications.
The gene repair pathway is initiated upon the introduction of naked DNA molecules into cells and their homologous alignment with a complementary sequence in a target gene; in some cases, the DNA pairing events creates a structure known as a D-loop (Figure 1) . 5 The strands pair in perfect register except for a single mismatched base pair, located in the center of the complex. D-loops in some form serve as reaction intermediates, with the potential for being resolved in several different ways. The resolution ultimately leads to a change in the targeted nucleotide (see below). It is fairly well established that the initialization of the reaction occurs through DNA pairing, a reaction catalyzed by proteins from the homologous recombination (HR) pathway. Our understanding of this phase comes largely from genetic studies in yeast that have revealed a role for proteins such as Rad51, 52, and 54. 6 showed that gene repair in CHO cells relies heavily on the HR protein, XRCC2. Thus, it now seems clear that DNA pairing, a part of HR pathway, is important for strand assimilation and the start of the gene repair reaction.
The cell normally uses HR to repair DNA damage resulting from double-strand breaks (DSBs) or stalled replication forks. Thus, one might predict that the activation of HR would also induce a higher level of gene correction and this appears to be the case. Ferrara et al 10, 11 showed that DSBs introduced through the action of the anticancer drugs, etoposide (VP16) or camptothecin (CPT) stimulated gene repair activity in DLD-1 cells. Suzuki et al 12 found that the anticancer drug bleomycin, which causes DSBs also stimulates the gene repair reaction by raising the endogenous levels of HR proteins in the cell. The biotechnology company Sangamo has reported that DSBs induced by chimeric zinc-finger nucleases increase gene correction dramatically. 13, 14 However, the introduction of breaks in the chromosomal DNA with the transient production of free ends may prove problematic for cellular metabolism and progression through the cell cycle (see below). Exciting data are appearing from labs exploring the use of rare-cutting endonucleases such as I-SceI and zinc-finger/FokI chimeras that can cleave genomic DNA at fixed (and Targeted gene repair: progress and prospects H Parekh-Olmedo et al few) locations. [15] [16] [17] [18] [19] It is possible that by minimizing the number of DSBs, the gene repair frequency will be elevated without the concurrent pleiotropic effects.
The events of the second phase where the 'correction' of the targeted mutant gene actually occurs are poorly understood. In this case, unfortunately, genetic data from yeast have not provided a clear picture of this phase of the reaction with some strains deficient in mismatch repair activity (MMR) exhibiting a low number of events, while other strains exhibit high correction frequencies. Studies in mammalian cells have also been confusing with cell-free extracts from certain cell lines deficient in MMR functions displaying low correction events, 2, 20 while studies in ES cells deficient in MMR function producing opposite results. 21 While these data appear contrary on one level, there is one unifying pathway that can reconcile some disparate results (see below).
Single-stranded DNA catalyzes gene repair most effectively
It is now clear that modified single-stranded DNA molecules generate the most reproducible and robust results, outperforming the original partially doublestranded structure. 22 Transition to single strands was prompted initially by in vitro studies on mechanism carried out by Gamper et al, and by results in mammalian cell culture (see Liu et al 2 and references therein). Important proof-of-concept experiments have been conducted in model systems where the repair of mutations in eGFP, 8, 23, 24 LacZ, 25, 26 HPRT, 27, 28 and retinoblastoma genes, 21 albeit at different frequencies, is effectively directed by a single-stranded vector. Partially duplexed oligonucleotides containing regions of singlestranded character have also been shown to be effective, but do not appear to be as active as the completely single-stranded molecule. 9 Short DNA fragments (SDFs) have also been used for catalyzing gene correction in a process labeled short fragment homologous recombination (SFHR). 29 SDFs are generated as PCR products with a typical length between 100 and 600 base pairs. The mechanism of action is unclear but considering the heterogeneity of the vector, it is not unlikely that it follows a similar pathway as oligonucleotides (see below). As we understand more about how the process is regulated, it may be possible to select vectors that produce the stable and robust correction rates in certain types of cells. 2, 20 In vivo applications of gene repair are being assessed During the last few years, exciting data have been reported when single-stranded DNA oligonucleotides were tested in animal models. Previous work led to the use of single-stranded DNA vectors in an animal model for the severe kidney disease carbonic anhydrasedeficiency (see Lai and Lien 30 for review). Beyond the successful demonstration of the technique and the reversal of the mutation detected at both the genotypic and phenotypic levels, no nephrotoxicity was found in the treated animals, as assessed by blood-urea nitrogen (BUN) levels and renal histology. Nevertheless, perhaps the most exciting results have come recently from studies using the gene repair technique to correct single-base mutations in liver cells. While some skepticism arose from early reports which reported an abnormally high frequency of gene repair activity in primary hepatocytes, the new data provide a scientifically sound foundation for considering liver cells as a primary target for the clinical applications of gene repair (see Andersen et al 20 
). Lu et al
31 demonstrated a specific nucleotide change and a dramatically altered phenotype directed by singlestranded oligonucleotides in the acid a-D-glucosidase gene in 0.5-4% of cells after tail vein injection. Importantly, both in vitro and in vivo (mouse) models were used to validate nucleotide alteration, which was confirmed at the DNA and enzymatic levels. These authors utilized an asialoglycoprotein receptor ligand to target hepatocytes, overcoming the problem in the liver. In a more recent study, Nakamura et al 32 observed conversion of the transthyretin gene in HepG2 cells and in a transgenic mouse, again clearly confirmed at the DNA and RNA levels. These results have generated considerable excitement and enthusiasm because the levels of conversion (9-11%) have immediate clinical benefits for familial amyloidotic polyneuropathy patients. However, not all animal models generate high levels of correction. Nickerson et al 33 have established a LacZ mouse model for testing gene repair activity and initial results were quite disappointing as no correction was detected using a variety of vectors. As portrayed by these authors, the delivery of the oligonucleotide in sufficient numbers to a particular tissue may be a continual problem for this approach.
Prospects: regulatory pathways will guide experimental design and clinical applications
The current challenge centers on the fate of the oligonucleotide paired at the target site and its role in the correction event. From our perspective, this is the most interesting and exciting area for future study as the answers may lead to an understanding of not only how it works but also which cellular factors are involved in its regulation. The phase in which a genetic change occurs should be labeled 'correction' because the product of the overall reaction is a corrected gene, not just an altered nucleotide.
Three possible fates for the oligonucleotide aligned at the target helix are presented below, with some evidence for each pathway (Figure 1) . Clearly, the level of transcriptional activity 34 and/or the movement of DNA replication forks 35, 36 could influence the route taken by the oligonucleotide. One pathway (Figure 1a ) involves a direct nucleotide exchange reaction that could be catalyzed by mismatch repair or nucleotide excision repair activities. In the schematic, the A residue of the oligonucleotide directs the conversion of a T in the Crick (C) strand; this pathway does not require extensive DNA replication and probably no transcriptional activity although both could assist in making the target site more available for oligo binding. The C strand then directs correction of the base in the Watson (W) strand from C-A. The reverse reaction is also possible, wherein the nonconverted gene status persists and no change in the sequence is made. Some evidence from studies in yeast supports a role for mismatch repair in the correction process, but, as stated above, not all the data support this model (see references in Liu et al 2 
In the second scenario (Figure 1b) , the oligonucleotide integrates into the W strand directly, then mediates a G-T switch on the C strand. Igoucheva et al 37 have proposed a model based on transcriptional activity. This involves DNA pairing, D-loop formation, resection of DNA, integration of the incoming oligonucleotide and repair of the mismatched base pair. This model attempts to explain the well-known 'strand bias' effect; oligonucleotides complementary to the antisense (AS) exhibit a higher level of gene correction than oligos targeted to the sense strand oligonucleotide and repair of the mismatched base pair. Such a model predicts that the AS strand would be heavily favored as the oligo target but recent data argue against this as the sense strand has been shown to be favored in some cases, 38 while no bias has been observed in others. 39 In fact, results from a study using the same LacZ system revealed that the strand bias actually switched when the target site was moved within the LacZ gene. 40 Perhaps, gene repair takes this route with genes that are highly transcribed, and is applicable only for genes driven by a CMV promoter in model systems or highly active promoters in natural genes.
The DNA replication process regulates gene repair activity
Recently, several reports have suggested that DNA replication can strongly influence the overall process of gene repair perhaps at multiple levels. 11, 36, 41, 42 In a passive role, one could envision that DNA replication functions simply to destabilize chromatin around the target site making it more accessible to the oligo. However, replication could play a more direct and dynamic role in the mechanism of correction. In light of the data presented below, we propose a novel pathway in the correction phase called the replication mode of gene repair (Figure 1c , right side of the diagram). In this scenario, initiation of the reaction would occur in a similar fashion to the other models as the oligo aligns to the site in the genome and creates a D-loop. In this case, however, the D-loop could be enveloped or bypassed by the replication fork, or may itself act as a signal for the binding of proteins that initiate origin firing (Figure 1d ). In either case, when the replication fork meets the Dloop, the oligo would be assimilated into the daughter strand between the Okasaki fragments of the lagging strand or at the 3 0 end of the leading strand. In the diagram, the W strand (leading or lagging) that is not bound by the oligonucleotides is simply displaced and replicated fully, generating an unconverted copy of the gene (Figure 1e) . However, the other strand contains the annealed oligo with the mismatched base pair complex.
In this example, the A/G mismatch could be repaired in two ways. Firstly, the A directs the conversion of the G residue to T in the C parental strand (Figure 1f) . The likelihood of this directional repair is probably low since current views of mismatch repair activity during DNA replication support the notion that the parental strand serves as a template to direct correction on the daughter strand resulting in no correction. 43 In this case, the results would be an uncorrected gene. Secondly, perhaps the most intriguing aspect of this pathway is the structure presented in Figure 1h . If we assume that the mismatch is tolerated through a single round of replication or MMR pathway is inactive, then a second round of replication could generate a corrected gene (Figure 1i ) and a parental noncorrected gene (Figure 1j) without DNA repair activity. In the final analyses, two rounds of DNA replication yield a converted gene in one of four cells. The important caveat of this scenario, however, is that the mismatched base pair created between the oligonucleotide and the target site is tolerated and is not resolved prior to the strands being replicated.
If this caveat is accepted, then one might predict that cells deficient in MMR would be able to tolerate the mismatch (it would be left unrecognized) and contain an inherently high level of gene repair activity. There is some evidence to support this notion. First, our own studies in yeast demonstrated that strains deficient in some MMR genes such as PMS1 supported enhanced levels of correction. Second, a mammalian cell system that has been used to characterize gene repair reactions is deficient in hMSH6 protein activity, yet this cell line produces consistently elevated levels of correction. 10 Third, Dekker et al 21 found that gene repair in MSH2À/À mouse ES cells is higher than in wild-type cells, and activity in MEF cells deficient in MSH2 is enhanced as compared to activity in wild-type MEF cells (Drury and Kmiec, unpublished observations). These data lend some support to a long held notion that MMR could act as a suppressor of gene repair by blocking homologous recombination in the form of DNA pairing. MMR proteins inhibit DNA exchange processes between divergent sequences perhaps by binding directly to recombination intermediates. Studies in yeast have clearly demonstrated that the MMR pathway, and MSH2 in particular, acts specifically to prevent assimilation of foreign DNA into the chromosome, a fundamental requirement of the initial phase of the gene repair reaction. Finally, in many of the gene repair assays, the C/C mismatch is 'repaired' quite efficiently 22, 25, 44 in contrast to the expected results based on mispair correction hierarchy. 45 This could infer that the replication mode is operational since the C/C mismatch is the least recognized mismatch and in this case, could be tolerated through several rounds of replication. Thus, cells deficient in MMR may enable the gene repair reaction to take place with higher efficiency.
The hybridization of the oligonucleotides to the target site requires a DNA pairing or DNA annealing function most likely provided by the homologous recombination pathway and HR has already been shown to increase the correction frequency. Court et al 3 proposed that short oligonucleotides assimilate into the lagging strand of replication forks and direct targeted mutagenesis in bacterial chromosomes and BACS. In view of the recent data, some of which is described above, it may now be appropriate to consider this route as a major pathway of gene repair in eucaryotes. Strand assimilation driven by members of the homologous recombination pathway is activated in response to DNA damage and coincidently would promote the initial phase of gene repair at a higher frequency. DNA lesions induced by drugs such as VP16 or CPT activate HR and retard, stall or inhibit replication. [10] [11] [12] 41, 42, 46 All these events elevate gene repair activity but are also subject to downregulation or even suppression by p53 or MSH2. While the evidence is sketchy, it is plausible that DNA damage other than simple mispairs could activate the suppressive MMR Targeted gene repair: progress and prospects H Parekh-Olmedo et al activity. 43 p53 and MSH2 have also found to be targeted to sites of replication-associated DNA recombination substrates. 47 It is likely that sites of active gene repair consist of stalled replication forks being acted upon by HR proteins and as such, the colocalization of suppressor functions by MMR could block HR and simultaneously inhibit gene repair events. This model would also predict that cells in S phase are more amenable to gene repair activity and recent data strongly suggest that this is the case. 24, 36, 42, 48 Correction-yes, but at what price?
As more and more systems are developed, the central questions about this technology are changing from does it work and how does it work, to what happens if it works? Our attention has been drawn to the last question by the insightful efforts of Olsen et al 9 who made, in our opinion, a critical observation about the inheritance of a corrected mutation. Alexeev and co-workers claimed to be the first to demonstrate permanent genotypic and phenotypic changes in mammalian cells. 37 This report infers that the corrected cells propagate and expand robustly, but, Olsen et al 9 found that the percentage of corrected cells decreases with time and y 'observed that apoptosis is coupled to the targeted sequence alteration rather than to general toxicity'. Such a phenomenon had been noticed previously but the data were not completely revealing and no clear explanation was offered to explain this observation. 49 However, if one considers the experimental protocols used to introduce the Non-specific oligo-Kan/LD50C
Specific oligo for eGFP mutation-EGFP3S/47NT
No oligo Supercoiled plasmid oligonucleotides, this type of cellular response should not be surprising but rather predicted. In the gene repair reaction, single-stranded DNA molecules are introduced at a high dosage and their presence obviously creates a molecular environment in which free ends abound. It is widely recognized that free ends induce a DNA damage response, which leads to cell cycle arrest, replication fork stalling and the activation of repair pathways, including HR. The combination of these activities determine the fate of the cell; whether the damage will be repaired or the cells will be programmed for death. 50 In effect, the cellular response to single-stranded vectors that direct gene repair is a double-edged sword. On the one hand, HR proteins are induced and help to catalyze the strand assimilation (perhaps into stalled forks), while on the other hand, their presence activates pathways that monitor genome integrity and could destroy the corrected cell. If true, one might predict that the correcting oligonucleotides would induce either ataxiatelangiectasia-mutated (ATM) or ataxia-telangiectasiamutated and Rad3-related (ATR) proteins which respond to cellular stress such as a break in the DNA itself or the stalling of a replication fork. 51 Recently, Ferrara et al (manuscript submitted) evaluated the induction of ATM in response to the introduction of oligonucleotides into DLD-1 cells. Cells were stained with an antibody directed against phosphorylated (activated) ATM and the data show clearly that the introduction of singlestranded oligonucleotides into a mammalian cell line induces the activation of ATM in contrast to supercoiled plasmid DNA or the electroporation protocol itself (Figure 2 ). Krauss and co-workers suggest that these corrected cells arrest at the G2/M border, 52 which could result from elevated levels of ATM. Earlier studies examined the effect of single-stranded DNA molecules on mammalian cells, and found that the cell responds to the presence of free ends by arresting cell growth, consistent with this interpretation of the gene repair reaction. 53 Thus, the cell may have to pay a price for achieving high levels of correction and this could explain why the technique has not been as reproducible as predicted from the early reports of success. It may also explain the low or variable levels of correction often obtained in different systems in which corrected cells may have survived to varying degrees prior to analyses.
Will this limit gene repair applications or can we bypass the checkpoint response?
As described above, new studies in animal models report sustained enzyme production as a result of genotypic changes and these alterations appear to be inheritable. 31, 32, 54, 55 One might wonder therefore if the activation of the cellular stress response is only valid for in vitro model systems. Reversing the stall by the use of reagents (caffeine) that allow the cells to pass through a G2/M block is one remedy. However, this may be unwise since this natural checkpoint prevents the transfer of unwanted mutations into daughter cells. Perhaps, the most logical strategy is to develop delivery systems that can transfer low amounts of oligonucleotide into the nucleus with high efficiency. It is likely that the movement of the oligo into the nucleus occurs inefficiently using current delivery methods as the oligo may be adsorbed to proteins or routed into terminal complexes. The challenge of oligonucleotide delivery has been the subject of several excellent reviews and the reader is directed to these important papers. 8, 32 The authors suggest physical delivery methods such as pluronic gels or nano-particles or the use of signal peptides conjugated to the oligonucleotide that will catalyze transfer to the nucleus. Interestingly, Davis and co-workers introduced several types of synthetic molecules, including the chimeric RNA/DNA oligonucleotide into CD34-positive cells using microinjection and succeeded in demonstrating that the targeted gene was altered precisely. 49 More importantly, the inheritance of the alteration persists as the cells were expanded in culture; a requirement of this approach is to be brought forward into clinic.
Conclusions and the future
Recently, Igoucheva et al 56 argued forcefully and we believe, correctly, for the development of better delivery systems and subsequent cellular expansion to achieve long lasting gene repair. This paper takes into account many of the challenges that workers face in this field and demonstrates the type of evaluation that must be undertaken before any disease target can be chosen with confidence. More emphasis needs to be placed on animal models that recapitulate human disease and realistic end points need to be put in place. Thus, gene repair has begun to face the same challenges that serve as barriers for many gene therapy applications, but several unique problems are now being recognized. Moreover, considering the history of this evolving field, one can only hope that these new challenges are met with more open and less frictional mindsets from both inside and outside the field, mindsets that have certainly stalled the development of this potentially important technique.
